146389-61-9|Zaragozic acid B|(1S,3S,4S,5R,6R,7R)-4,7-dihydroxy-1-((E)-4-hydroxy-3,5-dimethyl-8-phenyloct-7-en-1-yl)-6-(((6E,12E)-tetradeca-6,12-dienoyl)oxy)-2,8-dioxabicyclo[3.2.1]octane-3,4,5-tricarboxylic acid|-范德生物科技公司

Zaragozic acid B

NMR下载 COA and HPLC MSDS下载
names：
(1S,3S,4S,5R,6R,7R)-4,7-dihydroxy-1-((E)-4-hydroxy-3,5-dimethyl-8-phenyloct-7-en-1-yl)-6-(((6E,12E)-tetradeca-6,12-dienoyl)oxy)-2,8-dioxabicyclo[3.2.1]octane-3,4,5-tricarboxylic acid
CAS号：
146389-61-9
MDL Number：
MF(分子式)： C39H54O13 MW(分子量)： 730.84
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	(1S,3S,4S,5R,6R,7R)-4,7-dihydroxy-1-((E)-4-hydroxy-3,5-dimethyl-8-phenyloct-7-en-1-yl)-6-(((6E,12E)-tetradeca-6,12-dienoyl)oxy)-2,8-dioxabicyclo[3.2.1]octane-3,4,5-tricarboxylic acid
英文别名	Zaragozic acid B;
CAS号	146389-61-9
Inchi	InChI=1S/C39H54O13/c1-4-5-6-7-8-9-10-11-12-13-17-23-29(40)50-32-31(42)37(51-33(34(43)44)38(49,35(45)46)39(32,52-37)36(47)48)25-24-27(3)30(41)26(2)19-18-22-28-20-15-14-16-21-28/h4-5,10-11,14-16,18,20-22,26-27,30-33,41-42,49H,6-9,12-13,17,19,23-25H2,1-3H3,(H,43,44)(H,45,46)(H,47,48)/b5-4+,11-10+,22-18+/t26?,27?,30?,31-,32-,33-,37+,38-,39+/m1/s1
InchiKey	VFZAKIFLDMCTJV-NZHUAJKLSA-N
分子式 Formula	C39H54O13
分子量 Molecular Weight	730.84
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	Zaragozic acid B(CAS:146389-61-9):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	Zaragozic acid B is a fungal metabolite.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Suzuki T, Suzuki ST, Yamada I, Koashi Y, Yamada K, Chida N. Total synthesis of spicamycin. J Org Chem. 2002 May 3;67(9):2874-80. PubMed PMID: 11975540.

[2]Sakai T, Kawai H, Kamishohara M, Odagawa A, Suzuki A, Uchida T, Kawasaki T, Tsuruo T, Otake N. Structure-antitumor activity relationship of semi-synthetic Spicamycin derivatives. J Antibiot (Tokyo). 1995 Dec;48(12):1467-80. PubMed PMID: 8557605.

[3] Sakai T, Kawai H, Kamishohara M, Odagawa A, Suzuki A, Uchida T, Kawasaki T, Tsuruo T, Otake N. Synthesis and antitumor activities of glycine-exchanged analogs of spicamycin. J Antibiot (Tokyo). 1995 Jun;48(6):504-8. PubMed PMID: 7622437.

[4] Kamishohara M, Kawai H, Odagawa A, Isoe T, Mochizuki J, Uchida T, Hayakawa Y, Seto H, Tsuruo T, Otake N. Antitumor activity of SPM VIII, a derivative of the nucleoside antibiotic spicamycin, against human tumor xenografts. J Antibiot (Tokyo). 1994 Nov;47(11):1305-11. PubMed PMID: 8002395.

[5] Hornby JM, Nickerson KW. Enhanced production of farnesol by Candida albicans treated with four azoles. Antimicrob Agents Chemother. 2004 Jun;48(6):2305-7. PubMed PMID: 15155241; PubMed Central PMCID: PMC415631.

2: Hornby JM, Kebaara BW, Nickerson KW. Farnesol biosynthesis in Candida albicans: cellular response to sterol inhibition by zaragozic acid B. Antimicrob Agents Chemother. 2003 Jul;47(7):2366-9. PubMed PMID: 12821501; PubMed Central PMCID: PMC161837.

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开